ConductScience.org, home

Trial · NCT02160782

Results by group28

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18Randomized Withdrawal Period: MRX-21.73Standard Error 43.125μmol/L
Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18Randomized Withdrawal Period: Placebo95.55Standard Error 30.488μmol/L
Change From Baseline to Week 18 in Fasting sBA LevelsOpen-label Period: MRX Baseline283.43Standard Deviation 210.569μmol/L
Change From Baseline to Week 18 in Fasting sBA LevelsOpen-label Period: MRX Week 18192.50Standard Deviation 161.278μmol/L
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs)Open-label Period: MRX Baseline2.909Standard Deviation 0.5480Points
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs)Open-label Period: MRX Week 181.203Standard Deviation 0.8446Points
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt)Open-label Period: MRX Baseline2.903Standard Deviation 0.6616Points
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt)Open-label Period: MRX Week 180.831Standard Deviation 0.8122Points
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs)Randomized Withdrawal Period: MRX0.217Standard Error 0.2345Points
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs)Randomized Withdrawal Period: Placebo1.700Standard Error 0.2031Points
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt)Randomized Withdrawal Period: MRX-0.149Standard Error 0.3719Points
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt)Randomized Withdrawal Period: Placebo1.839Standard Error 0.2771Points
Change From Baseline to Week 18 in Alkaline PhosphataseOpen-label Period: MRX Baseline601.3Standard Deviation 274.77U/L
Change From Baseline to Week 18 in Alkaline PhosphataseOpen-label Period: MRX Week 18580.8Standard Deviation 215.50U/L
Change From Week 18 to Week 22 in Alkaline PhosphataseRandomized Withdrawal Period: MRX2.8Standard Error 22.55U/L
Change From Week 18 to Week 22 in Alkaline PhosphataseRandomized Withdrawal Period: Placebo-7.2Standard Error 20.31U/L
Change From Baseline to Week 18 in Alanine AminotransferaseOpen-label Period: MRX Baseline181.0Standard Deviation 108.56U/L
Change From Baseline to Week 18 in Alanine AminotransferaseOpen-label Period: MRX Week 18177.4Standard Deviation 92.08U/L
Change From Week 18 to Week 22 in Alanine AminotransferaseRandomized Withdrawal Period: MRX34.5Standard Error 14.04U/L
Change From Week 18 to Week 22 in Alanine AminotransferaseRandomized Withdrawal Period: Placebo19.4Standard Error 12.56U/L

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02160782/results